{
    "nctId": "NCT02810743",
    "briefTitle": "Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer",
    "officialTitle": "Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients With Personalized Therapy (SUBITO) - an International Randomized Phase III Trial",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 174,
    "primaryOutcomeMeasure": "Overall survival in all patients",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women and men with stage III adenocarcinoma of the breast harboring signs of a breast cancer with features of homologous recombination deficiency (HRD)\n* Age of 18-65 years\n* The tumor must be HER2-negative\n* Treatment must start within 8 weeks after the last surgical resection\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\nExclusion Criteria:\n\n* Previous radiation therapy\n* Previous chemotherapy\n* Any previous treatment with a PARP-inhibitor, including olaparib\n* Pre-existing neuropathy from any cause in excess of Grade 1\n* Chronic concomitant use of known strong or moderate CYP3A inducers",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}